124 related articles for article (PubMed ID: 9026268)
1. Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study.
Shikari M; Kushida K; Yamazaki K; Nagai T; Inoue T; Orimo H
Endocr J; 1996 Apr; 43(2):211-20. PubMed ID: 9026268
[TBL] [Abstract][Full Text] [Related]
2. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.
Orimo H; Shiraki M; Hayashi Y; Hoshino T; Onaya T; Miyazaki S; Kurosawa H; Nakamura T; Ogawa N
Calcif Tissue Int; 1994 May; 54(5):370-6. PubMed ID: 8062152
[TBL] [Abstract][Full Text] [Related]
3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
4. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
[TBL] [Abstract][Full Text] [Related]
5. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
[TBL] [Abstract][Full Text] [Related]
6. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3.
Orimo H; Shiraki M; Hayashi T; Nakamura T
Bone Miner; 1987 Oct; 3(1):47-52. PubMed ID: 3505192
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3].
Petkakov M; Popović V; Milić D; Damjanović S; Manojlović D; Mićić J
Srp Arh Celok Lek; 1995; 123(7-8):171-3. PubMed ID: 17974421
[TBL] [Abstract][Full Text] [Related]
8. [Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis--comparison with calcium preparations].
Nakatsuka K; Inaba M; Aratani H; Iba K; Sato T; Koike T; Miki T; Nishizawa Y; Morii H
Nihon Ronen Igakkai Zasshi; 1997 Jul; 34(7):569-76. PubMed ID: 9388377
[TBL] [Abstract][Full Text] [Related]
9. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
[TBL] [Abstract][Full Text] [Related]
10. 1-alpha-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women.
Chen JT; Shiraki M; Hasumi K; Tanaka N; Katase K; Kato T; Hirai Y; Nakamura T; Ogata E
Bone; 1997 Jun; 20(6):557-62. PubMed ID: 9177871
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease.
Sato Y; Manabe S; Kuno H; Oizumi K
J Neurol Neurosurg Psychiatry; 1999 Jan; 66(1):64-8. PubMed ID: 9886454
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation.
Sato Y; Maruoka H; Oizumi K
Stroke; 1997 Apr; 28(4):736-9. PubMed ID: 9099188
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.
Richy F; Schacht E; Bruyere O; Ethgen O; Gourlay M; Reginster JY
Calcif Tissue Int; 2005 Mar; 76(3):176-86. PubMed ID: 15692726
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
15. One year B and D vitamins supplementation improves metabolic bone markers.
Herrmann W; Kirsch SH; Kruse V; Eckert R; Gräber S; Geisel J; Obeid R
Clin Chem Lab Med; 2013 Mar; 51(3):639-47. PubMed ID: 23183751
[TBL] [Abstract][Full Text] [Related]
16. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).
Shiraki M; Orimo H; Ito H; Akiguchi I; Nakao J; Takahashi R; Ishizuka S
Endocrinol Jpn; 1985 Apr; 32(2):305-15. PubMed ID: 2995014
[TBL] [Abstract][Full Text] [Related]
18. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
19. Increased Serum 25(OH)D
Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
[TBL] [Abstract][Full Text] [Related]
20. Effect of 1 alpha-hydroxyvitamin D3 on loss of bone mineral density immediately after artificial menopause.
Kato T; Chen JT; Katase K; Hirai Y; Hasumi K; Ogata E; Shiraki Y; Shiraki M
Endocr J; 1997 Apr; 44(2):299-304. PubMed ID: 9228466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
